<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925883</url>
  </required_header>
  <id_info>
    <org_study_id>1R01CA218923-01A1</org_study_id>
    <secondary_id>R01CA218923</secondary_id>
    <nct_id>NCT03925883</nct_id>
  </id_info>
  <brief_title>Predicting and Addressing Colonoscopy in Safety Net Settings</brief_title>
  <acronym>PRECISE</acronym>
  <official_title>Predicting and Addressing Colonoscopy in Safety Net Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sea Mar Community Health Centers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prospective cohort study will evaluate the effectiveness of patient navigation in
      community health center settings. The investigators will collaborate with the advisory board,
      composed of key clinicians and patients, researchers, and policymakers, to establish a
      procedure to conduct and evaluate a patient navigation program that aims to increase rates of
      follow-up colonoscopy among diverse patient populations served by safety net clinics. Phase 1
      will be a milestone-driven planning process in which the investigators will validate the risk
      prediction model and apply the risk prediction model to stratify the patients and adapt
      patient navigation materials for the local context. Phase II will be a large-scale, patient
      randomized-controlled trial that will include 1200 patients at a large 34-clinic community
      health center in Washington State.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will fulfill the following aims:

      Aim 1: Validate externally the predictive risk score using Sea Mar CHC's robust data
      including 29,000 patients age-eligible for colorectal cancer screening; stratify patients
      according to risk of non-adherence to follow-up colonoscopy; and adapt patient navigation
      program for the local context.

      Aim 2: Assess the effectiveness, costs, and cost-effectiveness of a centralized, phone-based
      patient navigation program for follow-up colonoscopy receipt for patients at moderate risk or
      high risk for non-adherence.

      Aim 3: Assess differences in the intervention arms in secondary outcomes (e.g. time to
      colonoscopy receipt, no-show/canceled appointments, colonoscopy quality) and moderators of
      intervention effectiveness (e.g. probability level, intervention dose, and patient age,
      ethnicity, and sex)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of follow-up colonoscopy</measure>
    <time_frame>12 months</time_frame>
    <description>Receipt of colonoscopy within 1 year of abnormal Fecal Immunochemical Test (FIT) result</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Patient Navigation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this arm will receive patient navigation with the goal of completing a follow-up colonoscopy within 12 months of a positive FIT result.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive usual care screening opportunities</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Patient navigation</intervention_name>
    <description>Receive up to 6 live phone calls with a patient navigator for education, barrier assessment, and barrier resolution to follow up colonoscopy</description>
    <arm_group_label>Patient Navigation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive FIT test

        Exclusion Criteria:

          -  Prior colorectal cancer

          -  Dialysis patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria Coronado, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Center for Health Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer screening</keyword>
  <keyword>Cancer screening</keyword>
  <keyword>Risk prediction model</keyword>
  <keyword>Patient navigation</keyword>
  <keyword>Colonoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

